摘要
目的:探讨多药耐药基因产物Pg-p、GST-π、Topo-Ⅱ及CerbB-2和细胞增殖指数ki-67在胃癌组织中的表达及其临床病理学意义。方法:用免疫组织化学染色SP法检测上述指标表达情况。结果:Pg-p、GST-π与胃癌的Lauren的分型、病理分级和淋巴结转移无显著性差异(P>0.05),而与癌组织的浸润深度有显著性差异(P<0.05);Topo-Ⅱ与肿瘤的Lauren分型关系密切(P<0.05),与肿瘤的分化、肿瘤的浸润深度和淋巴结转移无关(P>0.05);CerbB-2、ki-67的表达与肿瘤淋巴结转移关系密切(P<0.05),而与胃癌的Lauren的分型、病理分级和肿瘤的浸润深度无关(P>0.05)。结论:联合检测多药耐药基因相关蛋白Pg-p、Topo-Ⅱ和GST-π以及检测CerbB-2、ki-67对判断胃癌患者预后和指导临床个体化治疗有指导意义。
Objective：To investigate the expressions of Pg-p,GST-π,Topo-Ⅱ,cancer gene CerbB-2,cell multiplication index ki-67 and the clinical pathology significance in stomach cancer.Methods： Their expression was examined by immunohistorchemistry method.Results： No remarkable difference in the positive expressions of Pg-p,GST-π were found with stomach cancer＇s Lauren divides,the pathology graduation and lymph node metastasis（P0.05）,but the depth of cancer infiltration had significance difference（P0.05）.No remarkable difference in the positive expressions of Topo-II were found with stomach tumor differentiation,and the lymph node metastasis（P0.05）,but the stomach cancer＇s Lauren divides had the significance difference（P0.05）.No remarkable difference in the positive expressions of CerbB-2,ki-67 were found with stomach cancer＇s Lauren divides,pathology graduation and the depth of cancer infiltration（P0.05）,but lymph node metastasis had the significance difference（P0.05）.Conclusion： There are great meanings to judge the stomach cancer patient prognosis and clinical treatment by union examination of Pg-p,Topo-Ⅱ and GST-π as well as CerbB-2 and ki-67.
出处
《现代肿瘤医学》
CAS
2011年第11期2281-2284,共4页
Journal of Modern Oncology
